Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

NPCE - NeuroPace Inc


IEX Last Trade
7.92
-0.030   -0.379%

Share volume: 35,623
Last Updated: Fri 30 Aug 2024 09:59:48 PM CEST
Surgical and Medical Instrument Manufacturing : -0.56%

PREVIOUS CLOSE
CHG
CHG%

$7.95
-0.03
-0.38%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
10%
Profitability 0%
Dept financing 25%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
2.86%
3 Months
21.10%
6 Months
-52.69%
1 Year
-8.01%
2 Year
88.57%
Key data
Stock price
$7.92
P/E Ratio 
-7.73
DAY RANGE
N/A - N/A
EPS 
-$1.09
52 WEEK RANGE
$5.75 - $18.15
52 WEEK CHANGE
-$0.11
MARKET CAP 
231.240 M
YIELD 
N/A
SHARES OUTSTANDING 
29.197 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
BETA 
1.27
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$45,847
AVERAGE 30 VOLUME 
$70,506
Company detail
CEO:
Region: US
Website: neuropace.com
Employees: 212
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Surgical and Medical Instrument Manufacturing
Sector: Manufacturing

the rns® system is an award-winning technology developed and manufactured in silicon valley that has been recognized for its innovation. similar to a pacemaker that monitors and responds to heart rhythms, the rns system is the world's first and only medical device that can monitor and respond to brain activity. neuropace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. the company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.in addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.

Recent news